Global Osimertinib
Market Report
2024
Osimertinib Market size is USD 4969.02 million in 2024 and will expand at a compound annual growth rate (CAGR) of 16.00% from 2024 to 2031.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
Share your contact details to receive free updated sample copy/pages of the recently published edition of Osimertinib Market Report 2024.
According to Cognitive Market Research, the global Osimertinib Market size is USD 4969.02 million in 2024 and will expand at a compound annual growth rate (CAGR) of 16.00% from 2024 to 2031.
Base Year | 2023 |
Historical Data Time Period | 2019-2023 |
Forecast Period | 2024-2031 |
Global Osimertinib Market Sales Revenue 2024 | $ 4969.02 Million |
Global Osimertinib Market Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 16% |
North America Osimertinib Market Sales Revenue 2024 | $ 1987.61 Million |
North America Osimertinib Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 14.2% |
Europe Osimertinib Sales Revenue 2024 | $ 1490.71 Million |
Europe Osimertinib Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 14.5% |
Asia Pacific Osimertinib Sales Revenue 2024 | $ 1142.87 Million |
Asia Pacific Osimertinib Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 18% |
South America Osimertinib Market Sales Revenue 2024 | $ 248.45 Million |
South America Osimertinib Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 15.4% |
Middle East and Africa Osimertinib Market Sales Revenue 2024 | $ 99.38 Million |
Middle East and Africa Osimertinib Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 15.7% |
Market Split by Type |
|
Market Split by Application |
|
Market Split by Distribution |
|
List of Competitors |
|
Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Osimertinib industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Osimertinib Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
The Osimertinib Market encompasses a segment of the over the projected period from 2023 to 2030; the Osimertinib Drugs Market Size is anticipated to rise at an astounding CAGR in terms of revenue and exponential market expansion. The world's growing need for Osimertinib drugs for hospital and drugstore applications is responsible for the market's expansion. The report provides information about the profitable prospects in the national Osimertinib Drugs Market. Accurate cost, segment, trend, region, and commercial development information for the leading worldwide players over the estimated time are also included in the research. Data regarding a market within one industry or across many industries is compiled and presented in the Osimertinib Drugs Market study.
Another significant driver shaping the Osimertinib Market is Many factors, including product pricing, product or service penetration at the national and regional levels, GDP of the country, market dynamics of the parent and child markets, end application industries, major players, consumer purchasing behavior, and the political, social, and economic environments of the various countries are taken into consideration in the preparation of this report. The research is broken down into many sections to provide a thorough examination of the market from every angle. .
In July 2020, AstraZeneca and Daiichi Sankyo formed a global development and commercialization partnership for the antibody-drug combination Daiichi Sankyo's Trastuzumab Deruxtecan (DS-8201).
One key driver in the Osimertinib Market is the continuous advancements in growth in the use of targeted treatments; more specialized treatments are being developed as a result of growing knowledge about the molecular causes of cancer. For some cancer types, targeted therapies have been demonstrated to be more successful than conventional chemotherapy. Generally speaking, targeted medicines have fewer adverse effects than conventional chemotherapy. As more targeted medicines are created and given the go-ahead for use, the market for targeted therapies is anticipated to rise over the next several years. The most prevalent kind of lung cancer is nonsmall cell lung cancer (NSCLC), and air pollution and smoking are contributing to its increased occurrence worldwide. More and more people are realizing that targeted medicines offer a better course of treatment for some cancers, such as NSCLC, with particular mutations.
Another key driver in the Osimertinib Market is the increasing number of NSCLC cases. Globally, nonsmall cell lung cancer (NSCLC) is the most common kind of lung cancer, contributing significantly to annual cancer diagnoses and fatalities. The number of NSCLC cases has increased for a number of reasons, including NSCLC; smoking continues to be the greatest risk factor. Even if smoking rates are falling in some areas, healthcare systems are nonetheless impacted by the lung cancer risk associated with prior smoking. New developments in diagnostics, such as low-dose C.T. scans, enable earlier NSCLC detection, which may increase the number of cases identified. There is also proof that exposure to air pollution, such as secondhand smoke and particulate matter, increases the chance of developing NSCLC. Concerns about air quality are expected to increase worldwide, especially in developing countries, and this will have an increasing effect on lung cancer diagnoses.
One key restraint in the Osimertinib Market is the challenge of unfavorable consequences and security issues. Of the side effects of osimertinib, diarrhea is one of the most frequent, occurring in 40–50% of patients. A considerable proportion of patients also report experiencing nausea and vomiting. These gastrointestinal adverse effects may impair treatment compliance and overall quality of life by causing malnutrition, electrolyte imbalances, and dehydration. Osimertinib use is often associated with rash and dry skin, affecting approximately 30–40% of patients. These skin responses may occasionally be severe enough to necessitate changing or stopping the treatment. Patients may have distressing side effects from dermatology that compromise their general well-being and sense of self.
The Osimertinib Market experienced both challenges and opportunities due to the impact of COVID-19. On the one hand, one targeted treatment that has been successful in treating some forms of lung cancer is osimertinib. When compared to conventional chemotherapy, it might provide a more individualized method of treating cancer with fewer possible adverse effects. Because lung cancer is becoming more common and targeted therapies are being more widely used, the market for osimertinib is predicted to expand. However, on the other hand, because osimertinib might be costly, some patients may not be able to afford the medication. There is a need for additional treatment options due to the concern surrounding the rise of Osimertinib resistance. Some patients may not have had access to Osimertinib or clinical trials because of the COVID-19 pandemic.
We have various report editions of Osimertinib Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
The competitive landscape of the Osimertinib Market is characterized by a diverse range of players competing to gain market share through product innovation, strategic partnerships, and aggressive marketing efforts. Key players in the market include established manufacturers, specialized companies, and emerging start-ups aiming to disrupt the market with innovative solutions.
In 2021, Oslerta, a generic form of osimertinib, was introduced in Bangladesh by Incepta Pharmaceuticals, a well-known pharmaceutical firm. With this launch, patients with EGFR-positive NSCLC would have access to a more cost-effective therapy option.
Top Companies Market Share in Osimertinib Industry: (In no particular order of Rank)
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue. Osimertinib and other successful medicines are in high demand due to the large number of lung cancer cases in North America. Osimertinib is more widely available to patients in this area thanks to insurance coverage and government initiatives. All of these elements work together to give North America the upper hand in the osimertinib business.
Asia-Pacific stands out as the fastest-growing region in the Osimertinib Market due to several compelling reasons. Firstly, Due to factors including smoking and air pollution, the incidence of lung cancer, a primary target for osimertinib, is on the rise throughout the Asia Pacific region. Patients now have easier access to pricey drugs like Osimertinib and healthcare as the economies in the area grow. Policies that increase access to cancer therapies, such as osimertinib, may be implemented by some Asian nations.
The current report Scope analyzes Osimertinib Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!
According to Cognitive Market Research, the global Osimertinib Market size was estimated at USD 4969.02 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 1987.61 million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.2% from 2024 to 2031.
According to Cognitive Market Research, the global Osimertinib Market size was estimated at USD 4969.02 Million, out of which Europe held the market of more than 30% of the global revenue with a market size of USD 1490.71 million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.5% from 2024 to 2031.
According to Cognitive Market Research, the global Osimertinib Market size was estimated at USD 4969.02 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 1142.87 million in 2024 and will grow at a compound annual growth rate (CAGR) of 18.0% from 2024 to 2031.
According to Cognitive Market Research, the global Osimertinib Market size was estimated at USD 4969.02 Million, out of which Latin America market of more than 5% of the global revenue with a market size of USD 248.45 million in 2024 and will grow at a compound annual growth rate (CAGR) of 15.4% from 2024 to 2031.
According to Cognitive Market Research, the global Osimertinib Market size was estimated at USD 4969.02 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 99.38 million in 2024 and will grow at a compound annual growth rate (CAGR) of 15.7% from 2024 to 2031.
Global Osimertinib Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Osimertinib Industry growth. Osimertinib market has been segmented with the help of its Type, Application Distribution, and others. Osimertinib market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Osimertinib Market Type Segment Analysis
According to Cognitive Market Research, 40mg*30 Tablets Type stands out as the dominating category. The majority of individuals should begin taking osimertinib at a dose of 80 mg once a day; however, some patients may need to have their dosage changed because of negative side effects, drug interactions, or other clinical factors. In such cases, a reduced dose of 40 mg is frequently administered, enabling patients to continue treatment at a dose that may be more tolerable. Dosage modifications or a lower initial dose may be necessary for older adults and patients with renal impairment. In order to reduce the possibility of side effects and guarantee proper drug exposure, the 40 mg dose is frequently recommended in various patient populations.
80mg*30 Tablets Type emerges as the fastest-growing category in the Osimertinib Market. For the majority of patients with nonsmall cell lung cancer (NSCLC) who carry particular EGFR mutations, which make up a sizable section of the osimertinib target patient population, the recommended starting dose is 80 mg once daily. One of the biggest causes of cancer-related fatalities globally is still lung cancer, especially nonsmall cell lung cancer (NSCLC). The need for efficient, targeted treatments like osimertinib is anticipated to increase in tandem with the rising global prevalence of nonsmall cell lung cancer (NSCLC), propelling the 80mg*30 Tablets market. Beyond its original clearance for EGFR mutation-positive NSCLC, osimertinib has been receiving regulatory approvals for other uses.
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Osimertinib Industry. Request a Free Sample PDF!
According to Cognitive Market Research, the dominating category is Metastatic NSCLC. Historically, the bigger patient population with metastatic nonsmall cell lung cancer (NSCLC) has dominated the osimertinib business. This is due to the fact that the illness has already become more aggressive after spreading to other organs. Osimertinib plus chemotherapy is a beneficial combination for the first-line treatment of locally advanced EGFR-mutated nonsmall cell lung cancer (NSCLC), as demonstrated by recent clinical trials such as FLAURA2. Higher osimertinib uptake in this patient population. The market for osimertinib for locally advanced NSCLC may expand in the upcoming years.
The fastest-growing category in the Osimertinib Market is Locally Advanced NSCLC. When existing EGFR tyrosine kinase inhibitors (TKIs) failed to control metastatic nonsmall cell lung cancer (NSCLC) with particular EGFR mutations, osimertinib was first authorized for this purpose. Nonetheless, osimertinib's effectiveness in the context of locally advanced NSCLC has been proven in subsequent clinical trials, prompting regulatory authorization for this use. Clinical research has demonstrated that osimertinib, as opposed to previous EGFR TKIs or chemotherapy regimens, can produce better results in the setting of locally advanced nonsmall cell lung cancer. Patients with EGFR mutations in nonsmall cell lung cancer (NSCLC) are increasingly being treated with targeted medicines such as osimertinib earlier in the course of their disease. Better disease control and longer survival times may be possible if the disease is targeted at an earlier stage, such as in locally advanced nonsmall cell lung cancer.
The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Osimertinib market report 2024 Edition by contacting our team.
According to Cognitive Market Research, the dominating category is online. The majority of nations have strict laws controlling the distribution and sale of prescription drugs over the Internet, particularly when it comes to specialty therapies like targeted cancer treatments. These rules are in place to guarantee appropriate monitoring, patient safety, and prescribing guidelines compliance. Pharmaceutical businesses typically avoid selling prescription medications to customers directly online because doing so could prevent the need for medical professionals to be involved in the therapy's prescription, counseling, and monitoring.
The fastest-growing category in the Osimertinib Market is Drug Store. Osimertinib is becoming more widely accessible through retail pharmacies and drug stores as it receives regulatory authorization and reimbursement coverage in new nations. This increased accessibility may stimulate market expansion in this area. Many patients find that getting their meds from a local pharmacy is more convenient than going to a hospital or specialist clinic, particularly those who are taking maintenance therapy or who live in distant places. The convenience element has the potential to fuel the drugstore segment's expansion. Expanding their networks of specialty pharmacies and drug stores, pharmaceutical companies want to provide patients with better access to targeted treatments such as osimertinib. This may contribute to the drugstore segment's expansion.
Senior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Disclaimer:
Type | 40mg*30 Tablets, 80mg*30 Tablets, 40mg*10 Tablets, 80mg*10 Tablets |
Application | Locally Advanced NSCLC, Metastatic NSCLC, Other |
Distribution | Drug Store, Online |
List of Competitors | Lonza AG, AstraZeneca, Drug International Limited, Everest Pharmaceuticals, Beacon Pharmaceuticals Limited, Incepta Pharmaceuticals Ltd |
This chapter will help you gain GLOBAL Market Analysis of Osimertinib. Further deep in this chapter, you will be able to review Global Osimertinib Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
Chapter 2 North America Market Analysis
Purchase Add-Ons to Customize the Report Edition and get further granular data level data about the North America market. Add-On Cost: Request before placing the order, Respective Pricing will be informed after sending the inquiry
Qualitative Analysis for the North America Market: North America Osimertinib Market Trends North America Osimertinib Technological Road Map North America Osimertinib Market Drivers North America Osimertinib Market Restraints North America Osimertinib Market Opportunity Market Attractiveness Analysis COVID – 19 Impact Analysis PESTEL Analysis Porter’s Five Forces Analysis Product Life Cycle Industrial Chain Analysis
You can purchase only the Executive Summary North America Market (2019 vs 2024 vs 2031)
Chapter 3 Europe Market Analysis
You can purchase only the Executive Summary Europe Market (2019 vs 2024 vs 2031)
Chapter 4 Asia-Pacific Market Analysis
You can purchase only the Executive Summary Asia Pacific Market (2019 vs 2024 vs 2031)
Chapter 5 South America Market Analysis
You can purchase only the Executive Summary South America Market (2019 vs 2024 vs 2031)
Chapter 6 Middle East and Africa Market Analysis
You can purchase only the Executive Summary Middle East and Africa Market (2019 vs 2024 vs 2031)
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
(Subject to Data Availability (Private Players))
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
Segmentation Type Analysis 2019 -2031, will provide market size split by Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Type Analysis 2019 -2031
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Application Analysis 2019 -2031
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Distribution Analysis 2019 -2031
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Osimertinib market
Chapter 13 Research Findings
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
Why 40mg*30 Tablets have a significant impact on Osimertinib market? |
What are the key factors affecting the 40mg*30 Tablets and 80mg*30 Tablets of Osimertinib Market? |
What is the CAGR/Growth Rate of Locally Advanced NSCLC during the forecast period? |
By type, which segment accounted for largest share of the global Osimertinib Market? |
Which region is expected to dominate the global Osimertinib Market within the forecast period? |
Segmentation Level Customization |
|
Global level Data Customization |
|
Region level Data Customization |
|
Country level Data Customization |
|
Company Level |
|
Additional Data Analysis |
|
Additional Qualitative Data |
|
Additional Quantitative Data |
|
Service Level Customization |
|
Report Format Alteration |
|
Published Report Editions
are Just a Tip of an Iceberg
Access the Complete Database of
Osimertinib Market
Request Sample